No Detail Found!

Exendin-4 Emerging Therapeutic Potential in Dermatology

Author(s)
Ahmed El-Sayed Hassan Sulaiman AlRajhi University, College of Medicine, Department of Basic Medical Sciences, AlBukayriyah, Qassim, Saudi Arabia; Zagazig University, College of Medicine, Department of Medical Physiology, 44519, Zagazig, Egypt
Eslam Kamal Fahmy Zagazig University, College of Medicine, Department of Medical Physiology, 44519, Zagazig, Egypt; Department of Physiology, College of Medicine, Northern Border University (NBU), 91431, Arar, Saudi Arabia
Mohammed M. Ismail Department of Anatomy, Faculty of Medicine, Northern Border University, 91431, Arar, Saudi Arabia
Mohammed M. Mosaed Department of Anatomy, Al-Azhar Faculty of Medicine, Al-Azhar University, Egypt; Department of Anatomy, Faculty of Medicine, Northern Border University, 91431, Arar, Saudi Arabia
Padmanabha B.V. Department of Physiology, College of Medicine, Northern Border University (NBU), 91431, Arar, Saudi Arabia
Baraah Abu Alsel Medical Sciences & Preparatory Year Department, North Private College of Nursing, 91431, Arar, Saudi Arabia
Basem Salama Department of Family and Community Medicine, Faculty of Medicine, Northern Border University, 91431, Arar, Saudi Arabia
Abstract
Exendin-4 is a synthetic analogue of the glucagon-like peptide-1 (GLP-1) that has a potent GLP-1 receptor agonist activity primarily approved for the treatment of Type 2 Diabetes Mellitus. Beyond its well-established metabolic actions, research has increasingly revealed the pleiotropic effects of Exendin-4, particularly in regulating inflammation, cellular proliferation, and tissue repair. Given that many dermatological conditions, including psoriasis and chronic wounds, share underlying pathogenic mechanisms such as systemic inflammation and impaired healing, the role of Exendin-4 in skin disorders presents a promising avenue for therapeutic exploration. This review examines the current evidence, primarily from in vitro and animal studies, regarding the direct and indirect influence of Exendin-4 on skin pathology, focusing on its impact on inflammatory dermatoses, wound healing and potential anti-cancer effects.
Publication Details
Page(s) 93-95
DOI DOI not available
Published Journal: Journal of Pioneering Medical Sciences, Volume: 15, Issue: 2, Year: 2026

Request the full text from PASTIC

Keywords
Skin Malignancies, Psoriasis, Wound healing, Skin Pathology, Exendin-4, Psoriasis
References
Eng J. .1990 .Purification and structure of exendin-3, a new pancreatic secretagogue isolated from Heloderma horridum venom. The Journal of Biological Chemistry, 265(33) : 20259-20262.
Eng J. .1992 .Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. The Journal of Biological Chemistry, 267(11) : 7402-7405.
Figat M. . .Beneficial influence of exendin-4 on specific organs and mechanisms favourable for the elderly with concomitant obstructive lung diseases. Brain Sciences, 12(2022) : 1090.
Yap M.K.K ,Misuan N. . .Exendin-4 from Heloderma suspectum venom: from discovery to its latest application as type II diabetes combatant. ” Basic & Clinical Pharmacology & Toxicology, 124(2019) : 513-527.
Chung C.H. .2024 .RETRACTED: Long-lasting exendin-4- loaded PLGA nanoparticles ameliorate cerebral ischemia/reperfusion damage in diabetic rats. ” Journal of Personalized Medicine, 12(2022) : 390.
Fu X. . .Dermatologic implications of glucagon-like peptide-1 receptor agonist medications. ” Skin Appendage Disorders, 11(2025) : 1-8.
Iwaya C. .2017 .Exendin-4, a glucagon-like peptide-1 receptor agonist, attenuates breast cancer growth by inhibiting NF-κB activation. ” Endocrinology, 158(12) : 4218-4228.
Faurschou S. . .GLP-1RAs in patients with psoriasis. International Journal of Molecular Sciences, 26(2025) : 3396.
Samotij D. . .Pathogenesis of psoriasis in the 'omic' era. Part I. Epidemiology, clinical manifestation, immunological and neuroendocrine disturbances. ” Postepy Dermatologii i Alergologii, 37(2020) : 135-153.
Buysschaert M. .2010 .Improvement of psoriasis during exenatide treatment in a patient with diabetes. ” Diabetes Care, 33(11) : e135.
Hogan A.E. .2011 .Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis. ” Diabetologia, 54(10) : 2664-2674.
Lin H. . .Anti-inflammatory effects of exendin-4, a glucagon-like peptide-1 analog, on human peripheral lymphocytes in patients with type 2 diabetes.” Experimental and Therapeutic Medicine. , 12(2016) : 3907-3912.
Burgess J.L. .2021 .Diabetic wound-healing science. ” Medicina (Kaunas), 57(10) : 1072.
Monroy L. .1871 .Effects of exendin-4 on diabetic wounds: direct action on proliferative phase of wound healing. ” Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, (2025) : 166946.
Hao H. .2017 .Exendin-4 in combination with adiposederived stem cells promotes angiogenesis and improves diabetic wound healing. ” Journal of Surgical Research, 212 : 19-28.
Sun Y. .2017 .Exendin-4 exhibits enhanced anti-tumor effects in diabetic mice. ” EBioMedicine, 19 : 130-139.
0

Citations

0

Downloads

17

Views